Pharma's Market
SPECIAL REPORT
MOST SHARED
- Wednesday's Economic News Crunch Could Tilt Markets
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Obama Reiterates Commitment to Boost US-India Ties
- The Social Media Gaming Threat
- NBA D-League On The Rise
- Japan Export Rebound Eases Fear of New Recession
- Stifling Anger at Work Can Kill, Survey Finds
- Australia Wheat Exporters Face Challenges: GrainCorp
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- 'Very Blah' Christmas Is Coming for UK Retailers
- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
- In Time for Holidays: More Gloom and Doom on Economy
PHARMA'S MARKET VIDEO
RSS FEED
Reporter
![]() |
CNBC.com Pharma Stocks |
Critics have been saying for years that big pharma's been pi..., er, throwing away money on relatively unproductive research and development of new drugs.
But a new study shows urine could eventually provide a new revenue stream.
The findings of the clinical trial, which Pfizer helped pay for, are being published in the "Proceedings of the National Academy of Sciences."
Researchers had 99 men between 18 and 64 years old pee in a cup.
Why 99? I have no idea.
All I can think of is the number of bottles of beer on the wall.
Anyway, the test subjects took acetaminophen, aka Johnson & Johnson's Tylenol.
And the clinical trial investigators had the men pee in a cup before they took the painkiller and for six hours afterwards.
They found a compound that comes from bacteria in the gut that presumably is a barometer of how each man metabolizes the Tylenol.
It gets rather complicated, but the researchers think the results could have future implications for figuring out who might respond to which drug.
The press release quotes a Pfizer VP of Research, Dr. Jeremy Everett, who says, "Although this is the first study of its kind and much further research is needed, this finding shows that in the future, researchers may need to consider human metabolic profiles as well as genetic profiles when choosing targets for drug discovery programs and when selecting patients for future clinical trials." 
Imagine the liquidity this could provide for companies like Quest Diagnostics, Lab Corp of America and Bio-Reference Labs if the practice were ever widely adopted.
So, what's this promising field of research called? Well, you might say it's the "Supercalifragilisticexpialidocious" of science. It's called, "Pharmacometabonomics." Great. Good luck with that.
Questions? Comments? and follow me on Twitter at mhuckman








